Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS
28/07/2022 13:36
July 28 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA
ACCEPTANCE FOR REVIEW OF NDA RESUBMISSION FOR ACER-001 FOR
TREATMENT OF UCDS
* ACER THERAPEUTICS INC - FDA DESIGNATED NDA AS A CLASS 2
RESUBMISSION AND SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA)
TARGET ACTION DATE OF JANUARY 15, 2023.
Source text for Eikon: ID:nGNX5CBZ3X
Further company coverage: ACER.O
(Reporting by Kannaki Deka)
((Kannaki.Deka@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31